FDA cleared the CXRDetectAI from Neurocareai, Inc. (Dba Savelife.Ai) on Jul 8, 2026 under K253751, a traditional 510(k). The device falls under product code QFM, Radiological Computer-Assisted Prioritization Software For Lesions, regulated at 21 CFR 892.2080 as a Class 2 device. The review panel was Radiology.

FDA logged the submission as received on Nov 25, 2025. The decision came 225 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

Neurocareai, Inc. (Dba Savelife.Ai) has 2 other decisions in the tracker over the last 12 months: K260936 (RadioViewAI), K252954 (MammoSightAI).